Royalty Report: Diagnostic, Drugs, Ultrasound – Collection: 129957

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Diagnostic
  • Drugs
  • Ultrasound
  • Biotechnology
  • Pharmaceuticals
  • Imaging
  • Medical
  • Cancer
  • Diagnostic Substances

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 129957

License Grant
Patent License The parties have entered into an agreement. Licensor has granted Licensee extensive rights to manufacture and distribute ultrasound contrast agents developed by Licensor.  Licensor hereby grants Licensee an exclusive, perpetual license under the Patents and the Know-How,- with right of sublicense, to make, use, develop, promote, and sell Optison in the Territory. This license is  noncancellable.

Trademark License Licensor hereby grants Licensee a perpetual royalty-free license to use any MBI trademark on or in connection with the manufacture, advertising, distribution, or sale of OPTISON pursuant to the exercise of the license granted.

License Property
Ultrasound Contrast Product means the ultrasound contrast agent currently under development under the name 'Sonazoid,' including any future-generation version thereof.

Optison means any product consisting of a stable hollow albumin microsphere filled with air or perfluoropropane that is substantially identical to the products manufactured by Licensor and sold to Licensee under the names 'Albunex-Registered Tradmark-' and 'Optison-Registered Trademark-' under ARDA II and its predecessors and that is used for the purpose of enhancing ultrasound images of the heart, other organs, and blood flow in clinical and veterinary applications.

US Patent #5,552,133  Method of making encapsulated gas microspheres useful as an ultrasonic imaging agent
US Patent #5,855,865  Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas
US Patent #5,730,955 Process for making gas-filled microspheres containing a liquid hydrophobic barrier
US Patent #5,674,469 Gas-exchange method of making gas-filled microspheres
US Patent #4,572,203 Contact agents for ultrasonic imaging
US Patent #4,718,433 Contrast agents for ultrasonic imaging
US Patent #4,774,958 Ultrasonic imaging agent and method of preparation
US Patent #4,844,882 Concentrated stabilized microbubble-type ultrasonic imaging agent
US Patent #4,957,656 Continuous sonication method for preparing protein encapsulated microbubbles
US Patent #5,820,850 Gas-filled amino acid block co-polymer microspheres useful as ultrasound contrast agents

Trademark        Country                Matter #        Status                Application        Filing
ALBUNEX           United States      24008.00       Registered        73/662,872        05/26/87
ALBUNEX &       United States      24018.00       Registered        74/397,650        06/04/93
DESIGN

Field of Use
This agreement pertains to the drug industry relating for the purpose of enhancing ultrasound images of the heart, other organs, and blood flow in clinical and veterinary applications.

IPSCIO Record ID: 1918

License Grant
If the Company is unable to manufacture Optison or Albunex in sufficient quantities to satisfy Mallinckrodt’s orders on a timely basis, Licensee may exercise certain contingent manufacturing rights; ultrasound contrast agents; is used to detect heart disease by assessing blood flow within the heart chambers and by identifying the location of the chamber borders and the movement of the chamber walls (cardiac function).  Under the distribution agreement, the Company is responsible for conducting clinical trials and securing regulatory approvals of the licensed products in the United States for cardiac indications, and Licensee is responsible for conducting clinical trials and securing regulatory approvals in the United States for non-cardiac indications and is responsible for conducting all clinical trials and securing approvals in the other countries in Licensee’s territory.
License Property
Albunex consists of air-filled albumin microspheres, is used during echocardiography (ultrasound imaging of the heart) to enhance the identification of endocardial borders and to assess blood flow within the cardiac chambers.   Optison is U.S. Patent No. 5,855,865, describes methods for making protein microspheres encapsulating certain perfluorocarbon gases, such as perfluoropropane, by ultrasonic or mechanical cavitation in the absence of oxygen.   Optison® is an  advanced-generation ultrasound contrast agent.
Field of Use
Licensee is responsible for conducting clinical trials and securing regulatory approvals in the United States for non-cardiac indications and is responsible for conducting all clinical trials and securing approvals in the licensed territory.

IPSCIO Record ID: 129744

License Grant
The German Licensor hereby grants Licensee a nonexclusive license under its Patent Rights to make, have made, use, import, distribute, sell, offer for sale and have sold the Product in the Territory, with no right to grant sublicenses, provided, however that, subject to the provisions, Licensee may grant a sublicense to other parties to market and sell the Product in the Territory, and further provided that they shall have no right to grant further sublicenses.

Licensor hereby grants Licensee a perpetual royalty-free license to use any MBI trademark listed ('Trademarks') on or in connection with the manufacture, advertising, distribution, or sale of OPTISON pursuant to the exercise of the license granted

License Property
Patent Rights shall mean the US Patent No. 4,276,885, and the Canadian Patent CA 1171952.  Product shall mean an ultrasound contrast agent consisting of albumin microspheres of fluorinated hydrocarbon and which is currently sold under the trade name Optison.
Field of Use
This agreement pertains to the drug industry relating to pharmaceutical specialties, including diagnostic substances and products as in an ultrasound contrast agent consisting of albumin microspheres of fluorinated hydrocarbon.

IPSCIO Record ID: 1548

License Grant
The Licensor granted Licensees of Norway exclusive developmental, manufacturing, and marketing rights for Albunex-Registered Trademark-and other gas-filled albumin microsphere ultrasound imaging agents in the territory.  In October 1995 the parties entered into an amendment of their agreement that effectively returned these rights to the Licensor.
License Property
Albunex is a proprietary ultrasound contrast agent which consists of air-filled albumin microspheres, is used during echocardiography which is an ultrasound imaging of the heart to enhance the identification of endocardial borders and to assess blood flow within the cardiac chambers.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 1549

License Grant
The Company entered into a license agreement with the Licensor, an individual, under which it acquired the exclusive right to develop, use and sell any products derived from patents and applications covering sonicated gas-filled albumin microspheres used for imaging and any future related patents and applications.  In June 1989, this agreement was restructured.
License Property
The microspheres are injected intravenously into the bloodstream and transported to the heart and other organs.  Because the microspheres are highly reflective to the ultrasound xbeam, organs and structures containing blood will appear more brightly and clearly than they would in the absence of the contrast agent.   Albumin is a protein naturally found in human blood and has been used for many years as a blood expander.

IPSCIO Record ID: 240619

License Grant
The Japanese Licensor grants to Licensees a non-exclusive license under the Licensor Patents to develop, make, have made, use, sell, offer to sell, and import Optison in the Territory. The grant of this license is expressly conditioned on the covenant not to sue set forth, and shall terminate automatically if that covenant of either Licensee or Licensee ceases to be effective for any reason.
License Property
Optison shall mean (i) an ultrasound contrast agent constituted as Optison is presently constituted and described in the application for U.S. Food and Drug Administration approval of same, together with such modifications thereto as may be made in connection with such application; (ii) an ultrasound contrast agent constituted as Optison is presently constituted and described in the application for U.S. Food and Drug Administration approval of same, but having a recombinant albumin shell together with such modifications thereto as may be made in connection with a Japanese MHW application or approval thereof; provided however that 'Optison' shall not include any product comprising perfluorocarbon gas other than perfluoropropane.

Licensor Products shall mean any ultrasound contrast agent comprising perfluoropentane (a/k/a dodecafluoropentane) developed, manufactured or sold by Licensor or its licensees.

Licensor Patents shall mean Korean patent no. 191,303, Taiwanese patent nos. 63,126 and 111,135, and any patents which may issue from Korean patent application no. 703129/95 or from the Licensor Japanese Patent Applications, or on any continuation or divisional application of them.

Licensor Japanese Patent Applications means Japanese patent applications nos. 05-506054, 06-517084, and 2000-150619.

Field of Use
This agreement pertains to ultrasound contrast agents.

IPSCIO Record ID: 30032

License Grant
The parties entered into this strategic alliance which covers Japan, Taiwan and South Korea, to develop OPTISON , as well as related products. The company granted an exclusive license to develop, manufacture, and market these products in the subject territory,
License Property
OPTISON is the only approved intravenous ultrasound contrast agent marketed in both the United States and Europe. Doctors and medical technicians use contrast agents primarily to improve the real-time images or moving pictures of organs and body structures. OPTISON is approved for use in ultrasound examinations of the heart.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 383590

License Grant
By this agreement, the Parties intend to enter into a restructured relationship.

For Patent License to Licensee of Germany, Licensor grants an exclusive license under the Licensor Patents and the Licensor Know-How to develop, market, sell, and distribute the Product in the Licensee Territory. Such license with respect to the TV Indication shall terminate on the Option 1 Effective Date, and, with respect to all of the countries of the world for all indications, excluding however the TV Indication, shall terminate on the Option 2 Effective Date.

For the Licensor HI Patents, Licensor grants a non-exclusive worldwide license, without a right to sublicense to any other party than Affiliates, under the Licensor HI Patents to use, develop, manufacture, have manufactured, market, sell and distribute product for use as an ultrasound contrast agent.

License Property
Licensor has certain technology for use in ultrasound imaging techniques.

AF0150 means a white powder which, after reconstitution with appropriate diluent, forms an aqueous suspension of perfluorohexane/nitrogen-filled microbubbles with the formulation employed in Phase II Clinical Trials under the United States IND 49,978.

CAD Indication means the indication of an ultrasound agent for the intravenous administration during two-dimensional gray-scale echocardiography examination including stress echocardiography for the differentiation of infarcted from ischaemic areas of the myocardium.

LV Indication means the indication of an ultrasound agent for manual intravenous administration during two-dimensional gray-scale echocardiography examination for improved assessment of global left ventricular function ( e.g. border delineation, ejection fraction, wall motion) at rest and during stress.

Product means AF0150 and any drug compounds, drug compositions and medical devices and systems related to perfluorocarbon containing ultrasound imaging products and developed by Alliance pursuant to this Agreement, and, with Licensee pursuant to the Original License Agreement, which, in the absence of this Agreement, the use, development, manufacture, marketing, sale or distribution of which would result in the infringement of one or more claims in an Alliance Patent or which utilize the Alliance Know-How. For ease of reference, Product is generally expressed in the singular in this Agreement, but multiple Products may be Developed or marketed hereunder.

Field of Use
The Field means, at any date of determination, the development, use, manufacture, distribution, marketing and sale of the Product as an ultrasound contrast agent in all possible indications, in humans or animals.

IPSCIO Record ID: 2662

License Grant
The Licensor hereby grants to the Licensee a license under Licensor's Patent Rights to make, have made, use, and sell Licensed Products within the United States and elsewhere throughout the world.
License Property
Licensor's Patent Rights, as used herein, means patent rights to any subject matter claimed in or covered by any of the following (a) U.S. Patent Nos. 4,572,203 entitled Contact (SIC) Agents for Ultrasonic Imaging issued February 25, 1986 (Appendix B),4,718,433, issued January 12, 1988, and 4,774,958, issued October 4, 1988, and any U.S. Patents resulting from the reissue or reexamination thereof; (b) Any current continuing or continuation-in-part applications or future continuing applications thereof; (c) Any patents issuing on said  applications or continuing or continuation-in-part applications thereof, including reissues; and (d) Any corresponding foreign patents or applications therefor.  The term Licensed Products, as  used herein, means any product, apparatus, kit or component part thereof, or other subject matter whose manufacture, use, or sale is covered by any claim or claims included within Licensor's Patent Rights.
Field of Use
The rights granted apply to the field of ultrasonic imaging and medical procedures.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.